C4 Therapeutics (CCCC) Other financing activities (2020 - 2026)
C4 Therapeutics' quarterly Other financing activities came in at $56000.0 in Q1 2026, down 48.62% year-on-year from $109000.0 in Q1 2025, and up 5500.0% quarter-over-quarter from $1000.0 in Q4 2025.
C4 Therapeutics has reported Other financing activities for 7 years, with the latest figure at $56000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 48.62% year-over-year to $56000.0; the trailing twelve-month figure through Mar 2026 stood at $221000.0 (down 45.7% YoY), and the FY2025 full-year result was $274000.0, down 28.27% from the prior year.
- Other financing activities for Q1 2026 stood at $56000.0, up from $1000.0 in the prior quarter.
- The five-year high for Other financing activities was $297000.0 in Q3 2024, with the low at -$1000.0 in Q4 2023.
- Average Other financing activities over 5 years is $111538.5, with a median of $104000.0 recorded in 2023.
- Year-over-year, Other financing activities surged 7433.33% in 2022 and sank 52.73% in 2023.
- Tracing CCCC's Other financing activities over 5 years: stood at $150000.0 in 2022, then plunged by 100.67% to -$1000.0 in 2023, then jumped by 200.0% to $1000.0 in 2024, then changed by 0.0% to $1000.0 in 2025, then surged by 5500.0% to $56000.0 in 2026.
- The last three Other financing activities figures came in at $56000.0 (Q1 2026), $1000.0 (Q4 2025), and $164000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 263,000.00 |
| Sep 30, 2023 | 263,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Mar 31, 2022 | 220,000.00 |
| Mar 31, 2022 | 220,000.00 |
| Dec 31, 2021 | -286,000.00 |
| Dec 31, 2021 | -286,000.00 |
| Sep 30, 2021 | 180,000.00 |
| Sep 30, 2021 | 180,000.00 |
| Jun 30, 2021 | 11.30 Mn |
| Jun 30, 2021 | 11.30 Mn |
| Mar 31, 2021 | -3,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Jun 30, 2020 | 4.50 Mn |
| Jun 30, 2020 | 4.50 Mn |